numer
human
infect
avian
influenza
virus
asia
recent
year
rais
concern
next
influenza
pandem
immin
effect
way
combat
influenza
vaccin
public
howev
minimum
month
need
develop
influenza
vaccin
use
tradit
eggbas
vaccin
approach
influenza
hemagglutinin
protein
ha
activ
ingredi
current
vaccin
express
insect
cell
use
baculoviru
express
vector
system
purifi
rapidli
influenza
vaccin
base
recombin
antigen
allow
time
respons
potenti
influenza
pandem
report
innov
monitor
assay
recombin
ha
rha
express
rapid
purif
process
variou
biochem
analys
indic
purifi
rha
properli
fold
biolog
activ
influenza
highli
contagi
acut
viral
respiratori
diseas
caus
signific
morbid
mortal
worldwid
year
influenza
virus
singlestrand
ribonucl
acid
rna
virus
surround
lipid
contain
envelop
spike
two
glycoprotein
hemagglutinin
ha
neuraminidas
na
glycoprotein
ha
particular
recogn
key
antigen
host
respons
influenza
viru
natur
infect
vaccin
virus
well
known
abil
mutat
circumv
immun
reinfect
host
antigen
shift
major
antigen
chang
viru
due
genet
reassort
two
subtyp
strain
coinfect
host
caus
influenza
pandem
sinc
popul
may
inher
immun
new
strain
avian
influenza
epizoot
outbreak
numer
human
infect
asia
recent
year
event
infect
two
nurs
attend
avian
influenza
patient
vietnam
march
possibl
persontoperson
transmiss
famili
cluster
diseas
thailand
continu
rais
concern
next
influenza
pandem
immin
proven
effect
way
combat
influenza
vaccin
public
use
trival
vaccin
produc
embryon
chicken
egg
current
process
three
influenza
strain
select
whocdc
propag
chicken
egg
chemic
inactiv
semipurifi
eggbas
technolog
howev
unabl
respond
pandem
crisi
vaccin
develop
product
take
sever
month
follow
identif
potenti
strain
typic
requir
reassort
high
yield
strain
obtain
adequ
growth
properti
minimum
month
need
develop
influenza
vaccin
use
approach
importantli
avian
influenza
strain
respons
recent
epizoot
outbreak
involv
numer
human
infect
lethal
chicken
egg
use
vaccin
product
chicken
lay
egg
sever
acut
respiratori
syndrom
sar
coronaviru
outbreak
serv
guid
next
influenza
pandem
like
global
consequ
spread
within
week
within
day
thu
system
rapidli
produc
new
influenza
vaccin
need
prevent
effect
reduc
impact
pandem
influenza
two
new
approach
shown
great
promis
replac
eggbas
techniqu
one
cell
culturebas
recombin
protein
antigen
base
cell
culturebas
approach
involv
product
influenza
virus
cell
cultur
follow
current
eggbas
viru
inactiv
purif
stream
process
advantag
cell
cultur
easier
handl
scale
short
period
time
influenza
vaccin
produc
approach
test
phase
phase
ii
clinic
trial
found
safe
least
effect
vaccin
produc
embryon
chicken
egg
limit
cell
culturebas
approach
process
still
requir
product
highyield
reassort
viru
process
also
may
introduc
cell
line
specif
mutat
gene
lead
select
variant
character
antigen
structur
chang
ha
protein
potenti
result
lessefficaci
vaccin
addit
hurdl
includ
product
handl
danger
viru
requir
avail
high
contain
facil
mammalian
cell
harbor
anim
virus
may
lead
safeti
concern
residu
express
cell
may
caus
unknown
sideeffect
sinc
thorough
purif
process
introduc
manufactur
process
hand
recombin
proteinbas
approach
involv
product
viral
antigen
ha
na
cell
cultur
recombin
dna
technolog
util
purifi
antigen
activ
ingredi
vaccin
rha
influenza
vaccin
develop
use
baculovirusinsect
cell
express
system
test
sever
phase
phase
ii
human
clinic
trial
involv
subject
demonstr
safeti
immunogen
efficaci
elderli
adult
rha
vaccin
equal
immunogen
eggbas
vaccin
treanor
jj
et
al
doserel
safeti
immunogen
trival
baculovirusexpress
influenza
viru
ha
vaccin
elderli
adult
manuscript
prepar
interestingli
two
rha
vaccin
deriv
two
strain
anew
provid
partial
protect
lethal
challeng
reconstruct
highli
lethal
pandem
influenza
viru
also
strain
mice
suggest
cross
protect
drift
strain
definit
feasibl
meet
challeng
potenti
influenza
pandem
howev
reliabl
express
system
quick
effici
downstream
purif
process
need
commun
report
rapid
process
capabl
purifi
rha
anew
ferment
puriti
within
h
overal
yield
sinc
chromatograph
media
use
chemic
stabl
commerci
avail
process
easili
scale
gmp
facil
variou
biochem
analys
indic
purifi
rha
properli
fold
biolog
activ
addit
also
develop
quick
simpl
analyt
assay
monitor
express
rha
insect
cell
ferment
ensur
rha
product
influenza
vaccin
strainanew
obtain
cdc
fulllength
ha
gene
contain
gene
influenza
virus
clone
use
rtpcr
insert
baculoviru
transfer
vector
develop
protein
scienc
corpor
special
vector
contain
promot
baculoviru
polyhedrin
gene
flank
sequenc
natur
surround
polyhedrin
locu
next
transfer
vector
cotransfect
insect
cell
linear
baculoviru
genom
dna
autographa
californica
nuclear
polyhedrosi
viru
deplet
polyhedrin
gene
part
essenti
gene
downstream
polyhedrin
locu
homolog
recombin
transfer
plasmid
linear
viral
dna
rescu
viru
result
recoveri
effici
recombin
viru
nearli
recombin
virus
select
plaqu
assay
plaquederiv
recombin
baculoviru
use
creat
viru
stock
infect
increasingli
larger
cultur
proprietari
insect
cell
expressf
deriv
cell
serumfre
cultur
medium
protein
scienc
fortifi
medium
viru
stock
use
infect
insect
cell
cellsml
produc
rha
applikon
bioreactor
multipl
infect
moi
viru
stock
experi
monitor
infect
process
express
ha
ml
sampl
taken
bioreactor
variou
time
one
millilitr
use
analyz
chang
cell
densiti
cell
viabil
cell
size
distribut
two
millilitr
centrifug
rpm
supernat
pellet
store
separ
c
use
srid
gel
blot
analysi
one
millilitr
use
hemadsorpt
analysi
rest
use
protein
purif
ml
ferment
sampl
insect
cell
uninfect
infect
recombin
baculoviru
contain
ha
gene
infect
recombin
baculoviru
contain
nonha
gene
ml
eppendorf
tube
ml
chicken
red
blood
cell
charl
riverspafa
north
franklin
ct
pb
ad
shaken
gentli
min
room
temperatur
end
incub
tube
flip
gentli
five
time
get
homogen
suspens
l
suspens
pipet
glass
plate
observ
microscop
olympu
optic
co
japan
three
repres
view
field
averag
insect
cell
count
field
reduc
chanc
fals
posit
insect
cell
attach
three
rbc
count
rbcbound
insect
cell
percentag
rbcbound
insect
cell
total
insect
cell
time
point
calcul
three
field
time
point
ml
ferment
sampl
analyz
autom
cell
analyz
cedex
innovati
gmbh
germani
cell
densiti
cell
viabil
cell
size
distribut
use
procedur
describ
manufactur
buffer
mm
sodium
phosphat
mm
edta
glycerol
ph
buffer
b
mm
sodium
phosphat
tergitol
glycerol
ph
buffer
c
mm
sodium
phosphat
mm
nacl
tergitol
glycerol
ph
buffer
mm
sodium
phosphat
glycerol
ph
buffer
e
mm
sodium
phosphat
glycerol
ph
buffer
f
mm
sodium
phosphat
glycerol
ph
buffer
g
mm
sodium
phosphat
mm
nacl
ph
sanit
buffer
nacl
naoh
unosphereq
biorad
hercul
ca
column
cm
cm
ml
spsepharos
fast
flow
geamershampharmacia
piscataway
nj
column
cm
cm
ml
hydroxyapatit
type
column
hxi
biorad
hercul
ca
cm
cm
ml
ferment
produc
rha
harvest
centrifug
h
postinfect
cell
pellet
g
extract
ml
tergitol
buffer
stir
magnet
stirrer
c
min
extract
clarifi
centrifug
g
min
supernat
load
qsp
column
equilibr
buffer
tandem
mlmin
load
column
wash
ml
buffer
column
disconnect
ha
elut
sp
column
ml
buffer
b
ml
buffer
c
consecut
qsp
column
regener
wash
column
volum
cv
sanit
buffer
cv
water
equilibr
cv
buffer
ha
fraction
buffer
b
ml
load
hxi
column
mlmin
column
wash
ml
buffer
b
ha
elut
hxi
column
increas
phosphat
concentr
buffer
e
f
ha
prepar
buffer
purifi
concentr
ultrafiltr
stir
cell
use
kda
mwco
regener
cellulos
membran
buffer
g
hxi
column
regener
wash
cv
water
equilibr
cv
buffer
c
rha
content
prepar
determin
srid
assay
describ
william
manchini
et
al
assay
base
diffus
rha
agaros
gel
contain
antibodi
ha
interact
antigen
antibodi
produc
precipit
ring
size
directli
proport
amount
antigen
appli
diamet
ring
srid
assay
determin
measur
magnifi
baushlomb
diamet
precipit
ring
use
determin
actual
concentr
base
standard
provid
center
biolog
evalu
research
fda
complet
deglycosyl
g
purifi
rha
deglycosyl
unit
peptidenglycosidas
f
pngase
f
new
england
biolab
beverli
usa
endoglycosidas
h
endo
h
new
england
biolab
c
min
describ
previous
limit
deglycosyl
g
rha
treat
g
trypsin
ice
min
digest
stop
ad
denatur
buffer
boil
min
trypsin
treat
rha
deglycosyl
unit
pngase
f
endo
h
ice
c
c
min
reaction
stop
ad
sd
sampl
buffer
boil
min
protein
speci
variou
deglycosyl
stage
resolv
sdspage
vaxigrip
influenza
vaccin
purchas
canada
drug
deliveri
nanaimo
bc
canada
puriti
rha
measur
sdspolyacrylamid
gel
stain
coomassi
blue
use
scan
laser
densitometri
model
biorad
hercul
ca
usa
peak
integr
analysi
total
amino
acid
analysi
carri
beckman
amino
acid
analyz
keck
facil
yale
univers
ntermin
amino
acid
sequenc
analysi
execut
protein
core
facil
columbia
univers
molecular
size
purifi
rha
analyz
sizeexclus
column
mm
tosahaa
japan
constant
flow
rate
mlmin
use
protein
molecular
weight
marker
refer
sigma
st
loui
usa
previous
describ
elut
buffer
mm
sodium
phosphat
mm
nacl
nan
trypsin
resist
assay
carri
incub
rha
min
c
without
gml
tpcktreat
trypsin
describ
copeland
et
al
assay
denatur
ha
produc
boil
rha
min
hemagglutin
activ
assay
done
essenti
describ
barrett
ingli
solut
fresh
chicken
red
blood
cell
ubottom
microtit
plate
critic
issu
product
therapeut
protein
use
recombin
dna
technolog
determin
harvest
ferment
earli
yield
may
suboptim
late
express
protein
may
degrad
varieti
proteas
releas
lytic
process
infect
cell
thu
rapid
sensit
assay
need
monitor
protein
express
choos
right
harvest
time
ha
well
known
abil
bind
sialic
acid
surfac
red
blood
cell
rbc
agglutin
cell
phenomenon
success
use
detect
cell
tissu
infect
influenza
virus
determin
whether
insect
cell
infect
recombin
baculovirus
contain
ha
gene
also
agglutin
rbc
uninfect
infect
insect
cell
incub
rbc
min
observ
microscop
uninfect
insect
cell
sampl
rbc
smaller
cell
scatter
around
slide
specif
bind
rbc
insect
cell
larger
cell
diamet
observ
shown
fig
hand
rbc
bound
insect
cell
infect
baculoviru
contain
ha
gene
deriv
influenza
strain
anew
fig
method
also
work
express
deriv
strain
fig
anew
data
shown
verifi
observ
hemadsorpt
due
ha
gene
gene
baculoviru
insect
cell
infect
recombin
baculoviru
contain
nonha
gene
also
incub
rbc
bind
rbc
insect
cell
observ
fig
observ
clearli
demonstr
rbc
bind
surfac
insect
cell
ha
express
depend
infect
depend
data
also
support
conclus
tabl
peak
hemadsorpt
cluster
insect
cell
agglutin
rbc
also
observ
later
bind
gradual
reduc
insect
cell
like
caus
breakdown
infect
cell
loss
cell
membran
evidenc
rapid
decreas
cell
viabil
determin
rha
level
ferment
sampl
time
singl
radial
immunodiffus
srid
assay
use
sinc
simpl
reproduc
techniqu
rel
unaffect
protein
crude
extract
consist
rbc
bind
insect
cell
correl
well
ha
level
determin
srid
late
ha
express
expect
ha
gene
regul
polyhedrin
promot
late
stage
promot
baculoviru
infect
similar
result
also
obtain
express
anew
data
shown
major
challeng
biotechnolog
industri
purif
biolog
activ
recombin
protein
ideal
purif
process
mild
effici
capabl
achiev
high
puriti
short
period
time
accordingli
purif
step
care
design
optim
whole
process
demonstr
hemadsorpt
studi
rha
express
fold
transport
cell
membran
late
stage
extract
rha
cell
membran
sever
nonion
deterg
variou
concentr
test
effici
best
result
obtain
use
tergitol
get
rel
clean
extract
magnet
stirrer
use
avoid
disrupt
cell
nuclei
organel
extract
clarifi
centrifug
remov
cell
nuclei
debri
ha
monom
anew
influenza
viru
strain
consist
amino
acid
theoret
molecular
weight
pi
therefor
rha
bound
cationexchang
media
like
sp
use
lower
ph
buffer
elut
higher
ph
buffer
achiev
primari
purif
concentr
supernat
extract
load
uno
sphere
qsp
column
tandem
anionexchang
q
column
act
scaveng
bind
negativecharg
impur
may
foul
sp
column
load
wash
column
detach
elut
separ
shown
chromatogram
fig
protein
flow
qsp
column
small
amount
protein
elut
sp
ph
buffer
rest
bind
tightli
either
sp
q
column
shown
sdspage
fig
rha
captur
sp
ph
select
elut
shift
ph
ph
shift
result
increas
puriti
base
densitometri
sdspage
gel
purifi
rha
use
hydroxyapatit
type
hxi
media
explor
bind
prefer
hxi
media
significantli
differ
ionexchang
media
yet
bind
elut
condit
rel
mild
preserv
biolog
activ
target
protein
thu
ph
sp
column
eluat
load
hxi
column
wash
rha
elut
column
increas
phosphat
concentr
shown
fig
rha
elut
mm
phosphat
small
loss
wash
mm
phosphat
elut
puriti
increas
accord
densitometri
sdspage
howev
still
protein
contamin
kda
prepar
reveal
lane
fig
sinc
size
rha
trimer
around
kda
differ
rha
size
impur
could
explor
remov
impur
thu
mm
phosphat
eluat
purifi
ultrafiltr
use
stir
cell
kda
mwco
demonstr
fig
kda
band
lane
select
remov
retent
purifi
rha
migrat
sdspage
gel
singl
polypeptid
rha
appar
molecular
weight
approxim
kda
blot
small
amount
cleavag
product
rha
also
observ
appar
molecular
weight
kda
respect
data
shown
trace
amount
rha
dimer
trimer
also
detect
appar
molecular
weight
kda
respect
summar
tabl
process
describ
purifi
rha
ferment
puriti
within
h
overal
yield
largest
singl
step
loss
column
confirm
authent
rha
purifi
protein
examin
ntermin
amino
acid
sequenc
total
amino
acid
analysi
aaa
ntermin
amino
acid
sequenc
match
predict
one
cycl
use
signal
sequenc
peptid
first
amino
acid
fulllength
ha
gene
absent
rha
measur
amino
acid
composit
purifi
rha
consist
theoret
one
data
shown
authent
rha
verifi
western
blot
use
anew
antibodi
provid
food
drug
administr
fda
purifi
rha
tweenpb
solut
analyz
use
sizeexclus
chromatographi
elut
singl
peak
min
shown
fig
correspond
molecular
weight
around
kda
like
complex
four
five
ha
trimer
kda
test
whether
purifi
rha
still
retain
nativ
structur
purifi
protein
treat
trypsin
ice
shown
lane
fig
rha
cleav
two
band
kda
kda
hand
heatdenatur
rha
digest
numer
small
fragment
trypsinresist
data
demonstr
rha
express
insect
cell
fold
properli
retain
nativ
structur
purif
tabl
stepwis
mass
balanc
hanc
purif
srid
assay
ha
gml
volum
ml
ha
mg
puriti
step
recoveri
total
recoveri
sinc
glycosyl
may
play
import
role
biolog
function
ha
interest
explor
whether
rha
produc
insect
cell
properli
glycosyl
thu
rha
deglycosyl
peptidenglycosidas
f
pngase
f
endoglycosidas
h
endo
h
resolv
sdspage
shown
fig
untreat
ha
migrat
kda
pngase
f
deglycosyl
ha
kda
endo
h
treat
ha
kda
respect
data
indic
rha
produc
insect
cell
inde
glycosyl
nlink
oligosaccharid
side
chain
kda
oligosaccharid
chain
high
mannos
content
suscept
endo
h
kda
oligosaccharid
chain
low
mannos
residu
resist
endo
h
assess
number
nlink
oligosaccharid
chain
trypsin
treat
rha
subject
limit
deglycosyl
pngase
f
endo
h
varieti
condit
sdspage
pngase
f
treat
sampl
fig
fig
three
distinguish
band
kda
one
band
kda
data
suggest
six
nlink
oligosaccharid
chain
region
two
high
mannos
content
one
nlink
oligosaccharid
chain
region
directli
compar
anew
caledonia
antigen
present
eggbas
vaccin
purifi
rha
anew
caledonia
formul
either
alon
ml
solut
g
rhabjiangsu
g
rhaawyom
ml
dosag
tm
expect
trade
name
protein
scienc
rha
vaccin
judg
hemagglutin
assay
activ
vaxigrip
licens
eggbas
vaccin
manufactur
sanofipasteuraventi
agglutin
rbc
prevent
form
tight
pellet
shown
fig
antigen
specif
srid
assay
wide
use
determin
concentr
activ
ingredi
vaccin
srid
gel
prepar
anew
antibodi
fig
diffus
ring
slightli
larger
vaxigrip
suggest
equival
vaxigrip
activ
ingredi
anew
strain
sdspage
fig
lane
clean
three
broad
band
visibl
repres
ha
three
strain
respect
vaxigrip
lane
complic
major
ha
band
around
kda
along
mani
minor
band
similarli
numer
impur
also
found
eggbas
vaccin
data
demonstr
purifi
rha
express
insect
cell
correctli
translat
properli
glycosyl
fold
biolog
activ
tradit
eggbas
vaccin
success
use
year
prevent
influenza
reliabl
effect
good
match
afford
howev
product
cycl
eggbas
vaccin
lengthi
heavili
depend
egg
suppli
unabl
develop
quickli
respons
urgent
need
influenza
pandem
replac
supplement
eggbas
vaccin
new
vaccin
equal
effect
reliabl
econom
capabl
develop
deliv
short
period
time
work
report
import
progress
toward
altern
influenza
vaccineth
recombin
proteinbas
vaccin
new
analyt
method
base
hemadsorpt
develop
close
monitor
express
ha
insect
cell
method
play
critic
role
ensur
optim
ha
product
determin
right
harvest
time
addit
harvest
paramet
hpi
cell
morpholog
viabil
also
success
use
protein
scienc
corpor
acceler
screen
process
recombin
baculovirus
use
ha
manufactur
purif
process
develop
quickli
purifi
recombin
ha
bulk
harvest
bioreactor
retain
biolog
activ
previous
ha
purif
heavili
depend
affin
chromatographi
use
specif
monoclon
antibodi
variou
lectin
method
highli
select
difficult
scale
commerci
level
due
number
limit
factor
ligand
leach
column
purif
must
remov
final
product
difficult
regener
affin
column
use
thu
perform
declin
use
batch
batch
variat
qualiti
affin
media
make
almost
imposs
robust
purif
process
time
time
affin
media
expens
use
larg
scale
hand
chromatograph
media
use
present
process
chemic
stabl
regener
repeatedli
commerci
avail
rel
inexpens
thu
suitabl
scale
gmp
facil
reagent
column
ancillari
equip
well
prepar
advanc
whole
purif
complet
one
full
work
day
avoid
overnight
storag
intermedi
rha
prepar
possibl
inactiv
rha
sever
factor
made
rapid
process
possibl
first
sampl
manipul
purif
step
make
quick
continu
purif
process
possibl
second
qsp
connect
tandem
combin
two
chromatograph
process
one
third
chemic
differ
chromatograph
mediahxi
use
differenti
rha
remain
impur
unlik
ionexchang
media
adsorpt
protein
hxi
involv
anion
cation
interact
calcium
group
interact
carboxyl
residu
wherea
phosphat
group
bind
basic
residu
surfac
protein
bound
protein
elut
increas
phosphat
gradient
gradient
calcium
magnesium
ion
worth
point
purif
process
describ
need
optim
largescal
product
exampl
tangenti
flow
filter
use
replac
stir
cell
polish
step
nonetheless
believ
strategi
describ
also
use
develop
rapid
purif
process
recombin
protein
biolog
activ
eggbas
vaccinevaxigrip
determin
hemagglutin
assay
base
srid
assay
equival
vaxigrip
activ
ingredi
anew
strain
influenza
challeng
studi
chicken
effect
protect
viru
infect
inocul
rha
viru
moreov
two
distantli
relat
rha
influenza
vaccin
use
baculovirusinsect
cell
express
system
also
demonstr
partial
protect
mice
lethal
challeng
recombin
pandem
influenza
viru
clinic
trial
trival
rha
vaccin
stimul
antiha
antibodi
product
least
well
case
rha
superior
tradit
eggbas
vaccin
influenza
season
phase
iib
field
trial
enrol
healthi
subject
age
show
dose
efficaci
prevent
cultur
posit
influenza
ill
compar
placebo
press
releas
protein
scienc
corp
june
furthermor
recombin
proteinbas
vaccin
describ
also
advantag
tradit
eggbas
vaccin
consist
sole
three
antigen
protein
store
steril
phosphat
bufferedsalin
without
preserv
thimeros
mercuri
deriv
current
use
eggbas
vaccin
antibiot
adjuv
unlik
eggbas
vaccin
live
influenza
virus
biocontain
facil
harsh
chemic
formaldehyd
use
manufactur
may
explain
shown
lower
side
effect
licens
vaccin
clinic
trial
therefor
reliabl
effect
afford
recombin
proteinbas
influenza
vaccin
develop
meet
challeng
potenti
influenza
pandem
pandem
prepared
develop
stockpil
rha
influenza
vaccin
present
strain
may
good
option
provid
protect
first
respons
personnel
popul
hardhit
area
case
pandem
win
preciou
time
manufactur
specif
influenza
vaccin
